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Evaluating Intended and Unintended Consequences of Health Policy and Regulation in 
Vulnerable Populations 
 
Abstract 
 
The objective of this dissertation is to evaluate whether two different types of policy 
interventions in the United States are associated with health service utilization and economic 
outcomes.   
Paper 1: The number of government lawsuits accusing pharmaceutical companies of off-
label marketing has risen in recent years. We use Medicare and Medicaid claims data to evaluate 
how an off-label marketing lawsuit and its accompanying media coverage affected utilization 
and spending on gabapentin as well as other anticonvulsant medications. In this interrupted time 
series analysis of dual eligible patients with bipolar disorder, we found that the lawsuit and 
accompanying media coverage corresponded with a decrease in market share of gabapentin, a 
substitution of newer and expensive anticonvulsants, and a substantial increase in overall 
spending on anticonvulsants.  
Paper 2: Medicare Part D was a major expansion of Medicare benefits to cover 
pharmaceuticals.  There were initial concerns about how the dually eligible population who 
previously had drug coverage through Medicaid would fare after transitioning to Part D plans.   
Using a nationally representative longitudinal panel survey of Medicare Beneficiaries that are 
dually eligible for Medicaid, we investigated whether differences in generosity of Medicaid drug 
benefits were associated with differential changes in drug utilization and out-of-pocket spending 
for duals after they transitioned to Part D.  Our finding suggest that those who previously 
encountered a monthly drug cap prior to Part D implementation experienced a differentially 
higher increase in annual prescription drug fills compared with those who did not face a cap. 
iv 
 
Paper 3: In this paper we evaluate how Part D may have been associated with 
antidepressant drug utilization for the disabled and elderly Medicare populations.  We found that 
the prevalence of antidepressant treatment did not change after Part D was implemented. 
However, we did find that antidepressant treatment intensity increased after Part D among both 
the elderly and nonelderly disabled subgroups.    
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Intended and Unintended Consequences of the Gabapentin Off-label Marketing Lawsuit 
Among Patients with Bipolar Disorder 
 
    
1
  
Abstract 
Objective: The number of lawsuits accusing pharmaceutical companies of off-label marketing 
has risen in recent years. The impact of such lawsuits on drug prescribing and spending has not 
been examined. We evaluated a nationwide sample to determine whether the $430 million 
gabapentin off-label marketing lawsuit and accompanying media coverage affected gabapentin 
market share, substitution of other scientifically substantiated and unsubstantiated 
anticonvulsants, and anticonvulsant spending in Medicare/Medicaid patients diagnosed with 
bipolar disorder. 
 
Method: Using a national 5% sample of Medicare recipients linked to Medicaid claims, we used 
an interrupted times series design to evaluate the impact of the lawsuit on monthly market share, 
utilization, and spending from January 1, 2001, to December 31, 2005. 
 
Results: The start of the lawsuit was associated with a 28% relative reduction in gabapentin 
market share (from ~21% to ~15%; p<0.001), and a reduction in the rate of prescribing from 108 
prescriptions per 1000 patients per month before the start of the lawsuit to 90 by the end of 
follow-up.  We also observed increases in market share for three other anticonvulsants. Total 
anticonvulsant use and spending per 1,000 patients increased by 13% and 74%, respectively, 
after the intervention.  The increase in anticonvulsant spending was equivalent to $8,184 per 
1,000 patients per year higher than expected compared with the baseline trend (p=0.01). 
 
Conclusions:  We conclude that the lawsuit resulted in a reduction in gabapentin market share, 
increased market share for other anticonvulsants, and substantially increased total anticonvulsant 
2
  
spending to approximately half of the settlement amount, not counting substitutions of newer 
drugs for other illnesses affected by the lawsuit.  These findings support the need for further 
study of the effects of current lawsuits regarding off-label drug marketing. 
 
  
3
  
Introduction 
The number of government lawsuits accusing pharmaceutical companies of off-label 
marketing has risen in recent years.
1-3
 Such lawsuits seek to recover costs of off-label drug use 
caused by illegal marketing.
4
 These lawsuits are often accompanied by widespread coverage in 
the lay media.  Negative media messages about medications have been shown to change 
prescribing patterns and sometimes reduce inappropriate drug use.
5-7 
   However, no studies have 
examined the impact of such lawsuits for off-label marketing (and accompanying media reports) 
on drug prescribing and spending.  Negative publicity from the lawsuits in marketing campaigns 
can increase market share of competitors’ products. We investigated the impact of the gabapentin 
off-label marketing lawsuit on gabapentin market share, substitution of alternative 
anticonvulsants with varying levels of evidence of efficacy in treating bipolar disorder, and 
changes in anticonvulsant spending in a nationwide sample of patients with bipolar disorder.  
Off-label prescribing is common in many conditions such as cancer, chronic pain 
management, and mental illnesses because scientific evidence supporting the use of some drugs 
for unapproved indications may exist even in the absence of a US Food and Drug Administration 
(FDA) indication.
8,9
 Physicians may judge medications to be effective for off-label indications in 
their practice despite the absence of scientific evidence because of similarities to other 
medications that have proven effective in the past. Although physicians can legally prescribe 
medications for off-label indications, it is illegal for companies to market a product for 
indications that are not FDA-approved.
4
 Regulation of off-label marketing through litigation has 
become increasingly prominent as pharmaceutical expenditures have grown. Given that policies 
that restrict use of unsubstantiated medications can increase spending due to substitution of more 
4
  
expensive similarly unsubstantiated medications, it is important to examine the intended and 
unintended consequences to such lawsuits.
10
  
Brief History of the Lawsuit 
  Gabapentin is an anticonvulsant medication that was approved in 1993 for adjunctive 
treatment of epilepsy and in 2002 for post-herpetic neuralgia. By 2000, gabapentin annual sales 
had grown to blockbuster status (nearly $1 billion), the vast majority of which were for off-label 
indications, such as bipolar disorder, various pain disorders, amyotrophic lateral sclerosis, 
attention-deficit/hyperactivity disorder, migraine, drug and alcohol withdrawal seizures, restless 
leg syndrome, and monotherapy treatment for epilepsy.
11
   In 1998, a former Parke-Davis 
employee filed a lawsuit against the company for illegally marketing gabapentin for use in off-
label indications. According to media reports, through which prescribers and patients would 
become aware of the lawsuit, the lawsuit was later unsealed in 2002 and the US Department of 
Justice and several states joined as plaintiffs.
3
  The plaintiffs sought reimbursement for the 
utilization that resulted from the illegal marketing. In 2004 Pfizer, having purchased Parke-
Davis, settled the lawsuit for $430 million, the largest off-label marketing settlement up to that 
time. 
Objective 
In this study, we hypothesized that the lawsuit, accompanied by widespread media 
coverage of the case (hereafter referred to as “the lawsuit”) from competing manufacturers, 
resulted in a reduction in prescribing of gabapentin. We chose to test this hypothesis in a 
population with bipolar disorder because gabapentin’s off-label use for this indication was 
unsupported in the scientific literature.
12-14
  In 2000, two randomized controlled trials
12,13
 were 
published that concluded that gabapentin was no different than placebo in the treatment of 
5
  
bipolar disorder. We further hypothesized that reductions in use of gabapentin would result in 
substitution of other anticonvulsants that may or may not have proven efficacy in the treatment 
of bipolar disorder.  Finally, we hypothesized that such medication substitution would lead to 
increased spending within the anticonvulsant class.  
Method 
Study Design 
 We used an interrupted time series design to evaluate the effect of the lawsuit on changes 
in level and trend of anticonvulsant market share and spending in patients with bipolar disorder.  
In a national experiment in which a control group is impossible, interrupted time series is the 
strongest quasi-experimental design available because it can control for pre-existing levels and 
trends of outcomes during the pre-intervention period when evaluating immediate changes in 
trends after the start of an intervention.
15
  
Data 
Using a merged dataset of a national 5% sample of Medicare (public insurance for the 
elderly and disabled) recipients and Medicaid (public health insurance for the low-income 
population) claims data from January 1, 2001, to December 31, 2005 we identified a 
continuously-enrolled, dually-eligible population over the age 18 years based on monthly 
enrollment data from Medicare and Medicaid. Continuous enrollment was defined as being 
enrolled in both Medicaid and Medicare in all months during the study period. We further 
analyzed Medicaid prescription drug claims for this population to measure anticonvulsant market 
share, utilization and spending.  These claims included a unique patient identifier, National Drug 
Code, date of dispensing, the number of units provided (number of tablets, for example), days' 
supply, and amount reimbursed.  
6
  
The Harvard Pilgrim Health Care Institutional Review Board approved the study, 
waiving consent because our study was conducted with de-identified patient data from a large 
administrative claims data set.  
 Study population 
The study population contains many of the sickest patients with bipolar disorder, a large 
number of whom qualify as permanently disabled.
16
 We limited the cohort to patients who had at 
least 1 inpatient or 2 outpatient diagnoses of bipolar disorder (ICD-9-CM codes 296.0, 296.1, 
296.4–296.7, 296.89, and 301.11) at any point during the study period.17,18 Diagnoses of bipolar 
disorder were accepted from the first diagnostic field in a claim.  
Information regarding sex, age and race of the study population were taken from the 
Medicare 5% sample data. Unique medications at baseline included medications for both 
physical and mental health and were taken from the claims data based on previously validated 
methods.
19
  
Study intervention index date 
The intervention was indexed when the lawsuit began in March 2002 (see Figure 1.1).
20
  
In order to identify trends in media reports of the lawsuit, we conducted a search of the Lexis-
Nexis database
20
 for newspaper articles and newswires that contained the words Neurontin and 
off-label between January 1, 1996, and December 31, 2005.  The search yielded 196 articles, of 
which 29 were excluded because they were unrelated to the lawsuit.  The first of many reports on 
this topic appeared in March 2002, shortly after the case was unsealed.
21
  Almost all coverage 
occurred in newspapers or newswires; television coverage was rare. 
 
 
7
  
Figure 1.1 Cumulative Number of News Articles in Lexis Nexis National Sample
19 
on 
Gabapentin Off-label Marketing Lawsuit : 1996 to 2005 
 
 
 
In June 2003, 15 months following the start of the lawsuit, the anticonvulsant lamotrigine 
was approved for bipolar maintenance by the FDA.
22
  Since this event would most likely affect 
anticonvulsant market share, we included this new indication in our analysis as a second 
intervention during the study period.  
Outcomes 
All study outcomes were calculated at monthly time intervals to allow the use of an 
interrupted times series design. We measured monthly market share as the fraction of total 
monthly prescription fills of anticonvulsants that each anticonvulsant represented. We chose to 
measure market share because it best reflects changes in relative use of individual products 
within a drug class.  We also measured overall utilization of anticonvulsant therapy and 
utilization of gabapentin.  We counted a month as a use month if that month was included 
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between the dispense date and through date on a prescription.  When looking at utilization, we 
counted each “use month” as a prescription. In order to characterize the level of scientific 
evidence of efficacy among the anticonvulsant medications used to treat bipolar disorder, we 
referred to the treatment recommendations from the National Institute of  Mental Health as well 
as several literature reviews. We identified several older anticonvulsants, including divalproex 
sodium, valproic acid, and carbamazepine, that were either approved for bipolar disorder or had 
been scientifically substantiated in the literature through publication of double-blind, randomized 
control trials that included results of efficacy in bipolar disorder.
23,24
 We also classified three 
anticonvulsants (topiramate, levetiracetam, and oxcarbazepine) as lacking evidence of efficacy 
for bipolar disorder.
25
 Finally, we included lamotrigine, which gained approval as a maintenance 
treatment in bipolar disorder during the study period.
22-24,26,27
  
We defined the following measures to describe spending.  Using the pharmacy 
reimbursed amount, we defined total anticonvulsant spending per 1,000 prescriptions per month, 
spending for each anticonvulsant per 1,000 prescriptions per month, and anticonvulsant spending 
per 1,000 people per month.   
Analysis 
We estimated population-level changes in anticonvulsant market share and spending 
using interrupted time series regression models.
15
  Using 14 months of data prior to the lawsuit, 
we established a baseline level and slope of market share and spending for anticonvulsants per 
1,000 patients per month.  We used segmented linear regression to evaluate changes in slopes 
and levels of anticonvulsant market share, utilization, and spending after the start of the lawsuit 
(March 2002) and the FDA-approval of lamotrigine for bipolar maintenance (June 2003), 
controlling for pre-intervention trends in market share and spending.  In the segmented 
9
  
regression, we controlled for serial autocorrelation and excluded all non-significant (p> 0.05) 
terms from the models by using backward elimination. We used SAS software, version 9.2 (SAS 
institute, Inc., Cary, North Carolina), to conduct these analyses. 
Results 
Descriptive statistics 
Table 1.1 describes several baseline characteristics of the study patients (N=3,004). The 
mean age was 48 years, ranging from 21-92.  Women comprised 62% of the population and 83% 
were white.  During the first year of the study period, patients took a mean of 10.8 unique 
medications.    
10
  
 
Gabapentin and anticonvulsant market share 
During the 14 months prior to the lawsuit, gabapentin was the second most prescribed 
medication (behind divalproex sodium) to the study population, representing 21.4% of 
anticonvulsant prescriptions.  During this baseline period, gabapentin market share remained 
  
Table 1.1 Baseline Characteristics of Study Cohort of  
Medicare and Medicaid Beneficiaries with Bipolar Disorder   
             
          
  
  Study cohort   
  
  (N=3,004)   
  
  
  
    
  
Characteristic   N    %  
             
          
  
Female  1,852    62  
  
        
  
Age at baseline         
  
20 - 34  536    18  
  
35 - 54  1,665    55  
  
55 - 64  345    12  
  
65+  458    15  
  
        
  
Race: White   2,499    83  
  
        
  
Medication use a         
  
Antipsychotics   1,987    66  
  
Lithium  744  
  
25  
  
Anticonvulsants   1,915  
  
64  
  
Antidepressants  2,384  
  
79  
  
Antianxiety   1,874  
  
62  
          
  
# Unique  medications b   
      
  
Mean (Standard Deviation)  10.77  (0.117)  
             
          a   Number of people who filled a prescription in each drug class  
at any point during the study period   
          b  Mean number of unique medications filled among the study  
population du ring the first year of the observation period   
    
11
  
stable between 21.4% and 22.6%.  However, gabapentin market share declined suddenly after 
the start of the lawsuit (see Figure 1.2) to 15.4% by the end of the study period, representing a 
relative change of -28% in market share (trend change = -0.16% market share per month, 
p<0.001).  In terms of gabapentin utilization among the study population, there was a reduction 
in the rate of prescribing from 108 prescriptions per 1000 patients per month before the start of 
the lawsuit to 90 prescriptions per 1000 patients per month by the end of follow-up (data not 
shown). 
Figure 1.2 shows a market share comparison of gabapentin, lamotrigine, and the 
unapproved anticonvulsants during the study period.  Lamotrigine utilization remained stable at 
2.5% during the baseline period.  After the start of the gabapentin lawsuit, the trend in 
lamotrigine market share increased immediately by 0.19% market share per month (p<0.001) and 
continued to increase after it received FDA approval for bipolar disorder treatment reaching a 
market share of 13.5% by the end of the observation period. Figure 1.2 also shows that the 
market share for the unapproved anticonvulsants (topiramate, oxcarbazepine, and levetiracetam) 
increased consistently from the start of the study period.  The upward monthly market share 
trend of +0.43% (p<0.001) continued after the start of the lawsuit and then decreased after 
lamotrigine received an FDA indication for bipolar disorder (trend change =   -0. 41%, p<0.001).   
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Figure 1.2. Market Share of Selected Anticonvulsants in the Dually Eligible Population with 
Bipolar Disorder: Gabapentin; Lamotrigine; and Unapproved Drugs  
 
This finding suggests that prescribers did not reduce off-label prescribing within this drug 
class as a result of the lawsuit. Overall it appears that lamotrigine and the unapproved 
anticonvulsants offset much of the decline in gabapentin market share.   The market share for the 
older approved anticonvulsants steadily declined during the baseline period (baseline trend=-
0.32% market share per month, p<0.001) and this decline slowed after the intervention (trend 
change = 0.24% market share per month, p=0.01) (Data not shown).  
Anticonvulsant use and spending 
Figure 1.3 shows the monthly utilization of anticonvulsants per 1,000 bipolar patients, 
mean monthly spending per 1,000 anticonvulsant prescriptions, and mean monthly spending on 
anticonvulsant treatment per 1,000 patients from February 2001 to December 2005.  Prior to the 
start of the lawsuit, monthly spending on anticonvulsants was consistently rising by $655.70 per 
1,000 patients each month. This upward trend further increased after the start of the lawsuit 
(trend change = $629.50 per 1,000 patients per month, p=0.01).  The dramatic increase in the 
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trend of anticonvulsant spending per 1,000 patients continued until lamotrigine was approved 14 
months after the start of the lawsuit (See Figure 1.3).  This trend change accounts for an $8,184 
increase in anticonvulsant spending per 1,000 patients compared with expected spending based 
on the baseline trend over the 13-month period before lamotrigine was approved for bipolar 
disorder.   
Figure 1.3. Overall Spending (per 1,000 prescriptions and per 1,000 patients) and 
Utilization of Anticonvulsant Drugs Among the Dually Eligible Bipolar Population 
 
The increase in anticonvulsant spending per 1,000 patients was largely due to substitution 
of expensive anticonvulsants as well as increased spending per prescription of gabapentin and 
lamotrigine.  The trend in gabapentin spending increased by $2,281 per 1,000 prescriptions per 
month, p<0.001 after the intervention. Lamotrigine spending increased in both trend (trend 
change = $3,035 per 1,000 prescriptions per month, p<0.001) and level (level change= $1,745 
per 1,000 prescriptions per month, p<0.001) (See Figure 1.4).  Figure 1.4 also shows that the 
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spending on the unapproved anticonvulsants was increasing $1,356 per 1,000 prescriptions per 
month before the lawsuit and this trend persisted after the lawsuit began. Spending on the older, 
commonly used standby anticonvulsants was increasing $748 per 1,000 prescriptions per month 
(p<0.001) and continued to increase after the lawsuit.  
15
  
Figure 1.4: Monthly spending per 1,000 prescriptions for all Anticonvulsants in the Dually Eligible 
Population with Bipolar Disorder: Gabapentin; Lamotrigine; Unapproved Drugs; and Older, Effective 
Medications  
 
 
Note: Lamotrigine is displayed separately because it gained an approval for bipolar maintenance during the study 
period. 
16
  
 
 
Discussion 
The importance of understanding the relationships between off-label lawsuits and media 
coverage, marketing, prescribing patterns and drug spending grows as off-label marketing 
lawsuits become more frequent.
28,29
  In the case of gabapentin, our results indicate that the 
lawsuit and accompanying media coverage corresponded with a decrease in market share of 
gabapentin, substitution of newer and expensive anticonvulsants, and an increase in overall 
spending on anticonvulsants.  
Our results also suggest that illegal off-label marketing lawsuits have both intended and 
unintended consequences.  Consistent with the US Department of Justice's intent to protect 
public insurers from fraudulent prescribing of gabapentin, the intended consequences of the 
lawsuit included a decrease in gabapentin market share as well as the substitution of alternative 
anticonvulsants.  However, as soon as information about the lawsuit was made available through 
media and marketing, there was a long-term, unintended increase in spending on anticonvulsants, 
which included a mix of scientifically substantiated and unsubstantiated products.    In this case, 
the increase in spending on anticonvulsant use most likely exceeded the settlement amount. On 
the basis of the national annual prevalence of bipolar disorder (2.6%)
30
 and the observed 
approximate increase in spending immediately following the intervention ($7,554 per 1,000 
patients per month) we estimated that the increase in spending on anticonvulsants during the 
observed post- intervention period was well over $200 million: about half of the $430 million 
gabapentin settlement amount, not counting many unmeasured substitutions in other illnesses 
affected by the lawsuit. 
17
  
Despite evidence from physician self-report that off-label use of gabapentin in bipolar 
disorder was unaffected by the lawsuit,
31
 our results show a reduction in use of gabapentin from 
21.4% to 15.4% market share (28% relative reduction) after the lawsuit, following a period of 
stable use during the baseline period.  
The relative decrease in gabapentin use did not coincide with a decline in overall 
anticonvulsant use; we showed that the market share of other anticonvulsants increased or 
continued to grow after the intervention. This increase is not surprising because of previous 
studies that show the decline in use of 1 drug after regulatory changes is often offset by 
increasing utilization of other substitute drugs.
10,32,33
 Lamotrigine, an off-label, brand-name 
anticonvulsant that later received an indication for bipolar disorder in 2003 (more than a year 
after the gabapentin lawsuit), was 1 of the drugs that experienced the highest increase in market 
share.  The use of the unapproved anticonvulsants, which included three brand name medications 
with no indication for bipolar disorder also continued to increase substantially after the 
intervention.  Thus, many prescribers shifted from 1 scientifically unsubstantiated product to 
both substantiated and unsubstantiated products. The continued use of off-label prescribing 
indicates that the negative coverage did not result in a generalized reduction in off-label 
medication use. It is not surprising that the lawsuit was not associated with an increase in market 
share of older, generic medications that are not generally promoted as intensely as branded 
medications by the pharmaceutical industry.
34
 
Monthly anticonvulsant spending per 1,000 patients increased 74% after the start of the 
lawsuit.  Since a major driver of the lawsuit was state Medicaid program reimbursement of 
excess spending for off-label gabapentin use from 1994-2002, the increase in spending for 
anticonvulsants was unexpected.   
18
  
This study has several limitations. Our datasets did not allow us to measure 
pharmaceutical spending on marketing for anticonvulsants.  Marketing to psychiatrists for 
gabapentin was essentially discontinued after the publication of the 2 negative randomized 
controlled trials 
35
 and may have contributed to the stability in use of gabapentin during the 
initial period of this study.   However, there was most likely an increase in marketing of other 
anticonvulsant drugs in anticipation of decreased gabapentin use.  We also could not account for 
changes to state Medicaid pharmacy benefits.  For example, several State Medicaid Programs 
implemented prior authorization policies that included gabapentin, but these programs were 
implemented near the end of our study period after the lawsuit was settled in 2004 and were 
unlikely to affect our results.
35 
  Like lamotrigine, several antipsychotics (risperidone, quetiapine, 
ziprasidone, and aripiprazole)
36
 were approved for bipolar disorder during the study period.  
Since these approvals could potentially influence our outcomes, we conducted a sensitivity 
analysis in which we included new bipolar medication approvals that occurred during the study 
period as interventions and evaluated changes in drug-specific market share and spending using 
all bipolar drugs in the denominator for market share.  This analysis did not change our 
conclusions with regard to the anticonvulsant drug class, so we chose to exclude these 
interventions in the study.  Also, we recognize that the publication of 2 studies
12,13
  suggesting 
that gabapentin was not efficacious may have affected prescribing of gabapentin; however, these 
studies occurred before our baseline period when gabapentin use was flat and stable. Spending 
was based on pharmacy reimbursement, so we could not account for rebates.  We did not have 
any information about physician specialty, so we were unable to distinguish between 
anticonvulsants prescribed by psychiatrists and those prescribed by general practitioners. 
However, other studies of this population indicate that most patients with bipolar illness are 
19
  
generally treated by mental health specialists.
37
  Another limitation was that the pre-intervention 
period was relatively short; however, use of all medications was very stable and easy to model 
with the available data.  We recognize that the dually eligible population with bipolar disorder is 
a particularly vulnerable subpopulation among those diagnosed with the disorder. While we 
believe that the general pattern of substitution effects in the general population may be similar, 
further study is needed to generalize our findings beyond this population. 
In 2006 a year after our study period ended, Medicare Part D, the largest change to 
Medicare coverage since its inception, was implemented.  Under this policy, the dually eligible 
population was transitioned from state Medicaid pharmacy benefits to regional Part D drug 
plans.  Since both state Medicaid pharmacy benefits and Part D Plans vary widely in their 
formularies and cost-containment strategies, we believe it would be very interesting to evaluate a 
more recent lawsuit to observe whether similar intended and unintended consequences of this 
type of litigation would occur during the Part D era.  
The US Department of Justice continues to sue pharmaceutical companies for off-label 
marketing practices.  AstraZeneca, Pfizer, and Serono recently settled cases for hundreds of 
millions of dollars.
28,29,38
  In 2010, Novartis settled a lawsuit accusing Novartis of marketing 
oxcarbazepine for off-label use in bipolar disorder.
1
  The impact of these later lawsuits and their 
accompanying media coverage on prescribing practices remains unknown.  On the basis of these 
results, the gabapentin lawsuit was associated with both intended and unintended changes in drug 
utilization and spending.  This finding highlights the need for more comprehensive consideration 
of potential consequences when the US Department of Justice and states negotiate these 
important settlements. We found that both on-label and off-label anticonvulsants substituted for 
gabapentin use, and spending increases for other anticonvulsants eclipsed the reimbursement to 
20
  
states for off-label gabapentin use.   These findings suggest the need for further study of lawsuits 
for the pharmaceutical marketing of off-label indications. We suggest that in these types of 
lawsuits, the US Department of Justice communicates with relevant health care provider and 
specialty organizations rather than rely on media reports as a primary means of disseminating 
information about an illegal marketing case. With knowledge of such a case, the health care 
provider organizations could inform prescribers about the litigation and reinforce that prescribers 
should refer to treatment guidelines for the disease of interest when making decisions about off-
label prescribing. A narrow regulatory approach that does not consider the prescribing needs and 
substitution behavior of clinicians may not be effective in decreasing the use of scientifically 
unsubstantiated drugs and may increase rather than decrease overall spending.  
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Paper 2 
 
 
 
 
 
Dual Enrollees and the Transition to Medicare Part D: The Influence of Prior State 
Medicaid Benefits on Changes in Use of Medications 
25
  
 Abstract 
 
Objective: In this study, we evaluate how transitioning from state Medicaid drug benefits with 
and without drug benefit limits differentially affected changes in medication use and out-of-
pocket drug costs among Medicare/Medicaid dual eligibles after their transition to Medicare Part 
D in 2006. 
 
Methods: Using the Medicare Current Beneficiary Survey (MCBS) from 2000 to 2007, we 
identified annual cohorts of community-dwelling dual eligibles. Outcome measures were average 
annual prescription drug fills and out-of pocket drug costs per person.  We constructed time-
series regression models using pre-Part D data (2000-2005) to establish a baseline trend and 
intercept. We used these models to estimate predicted values to compare with observed values 
for each outcome in 2007.   
 
Results: Dual enrollees in states with no Medicaid caps had an average of 4.4 more prescription 
drug fills in 2007 than expected given baseline trends for 2000-2005.  In contrast, dual enrollees 
in states with Medicaid caps had an average of 10.5 more prescription drug fills in 2007 than 
expected.  Both state groups experienced decreased total out-of-pocket spending on medications 
after Part D (absolute decreases –$143 and –$40, respectively).  
 
Conclusions: Our study indicates that the dual eligibles in states with caps on the number of 
covered fills per month prior to entering a Part D plan experienced larger increases in annual fills 
compared with those in states where pharmacy benefits, like Part D plans, were not capped.  This 
suggests that state Medicaid caps impose substantial constraints on the use of prescription 
26
  
medications for dual eligibles, which in turn may lead to under treatment of illness and adverse 
health consequences for individual patients. 
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Introduction  
In 2006 Medicare expanded its benefits to offer pharmaceutical coverage (Medicare Part 
D) to its beneficiaries, many of whom had no insurance coverage for prescription drugs.
1,2
 Low-
income elderly and persons with disabilities who are enrolled in both Medicare and Medicaid- 
received drug benefits through their state Medicaid pharmacy program. As part of the 
implementation of Part D in 2006, these dual eligibles were automatically transitioned from their 
state Medicaid pharmacy benefits to a regional Part D prescription drug plan (PDP).
3
   At the 
time of Part D implementation there were approximately 6.6 million duals assigned to a Part D 
PDP.
4
   
While it seemed likely that Medicare beneficiaries who transitioned from no insurance to 
Medicare Part D would experience increased access to medicines, it was not clear what the 
impact would be for the dual population who had previously had Medicaid drug coverage. 
Because these dual beneficiaries are among the sickest and poorest of the Medicare beneficiaries, 
many policymakers and others were concerned that they might experience reduced access to 
essential medicines from this change.  Policymakers and others raised concerns that dual 
enrollees might have difficulties navigating the new system; cease use of essential medications 
because of increased cost sharing; and have trouble accessing essential medications under new 
formulary restrictions.
5-7
  Previous studies of the impact of Medicare Part D on access to 
medicines for the dually eligible population have found that, on average, dual eligibles 
experienced either the same or increased utilization of medicines after Part D compared with 
their utilization before Part D.
8,9
 However, no study has examined the impact of Medicare Part D 
on the duals while considering differences among the Medicaid pharmaceutical benefits from 
which they transitioned.   
28
  
State Medicaid pharmacy programs commonly use several utilization management 
strategies in order to minimize excess prescribing and control drug spending.  These strategies 
include copayments, restricted formularies, prior authorization (requiring approval from the 
program before a particular drug can be dispensed), and prescription drug caps.
10,11
 A drug cap is 
a limit on the number of prescriptions per person that a Medicaid program will pay for each 
month.  When dual beneficiaries transitioned into a Medicare PDP in 2006, they encountered 
modest copayments for each medication they filled ($1-$5; the maximum copayment has since 
increased to $6.30),
12,13
 drug formularies, and some prior authorization requirements depending 
on their PDP.  But there are no drug caps under Part D. Previous studies have found that cap 
implementation in state Medicaid programs was associated with an immediate drop in drug 
utilization.
14
 Removal of the cap was also associated with a dramatic and immediate increase in 
medication use.
14
   
In this study we evaluated how transitioning from Medicaid programs with and without 
drug caps affected prescription drug utilization for dual eligibles entering Medicare Part D.  We 
also evaluated overall changes in out-of-pocket (OOP) spending before and after Part D.  We 
hypothesized that in state Medicaid programs with prescription drug caps, the dual eligibles 
would experience a differentially larger increase in utilization once enrolled in PDPs in 2006 
compared with dual eligibles in states that had previously had no Medicaid drug caps.    
 
Methods 
Study Design 
We used time series regression on the data from 2000 to 2005 to establish baseline 
intercepts and trends for our outcomes during the pre-policy period.  Using bootstrap models we 
predicted post-policy outcomes in order to evaluate the effects of the transition to Medicare Part 
29
  
D on prescription drug use and OOP costs among dually-enrolled beneficiaries in states with 
drug benefit programs that varied in generosity.   
Data and study population  
Using the Medicare Current Beneficiary Survey (MCBS) from 2000 to 2007, we 
identified annual cohorts of community-dwelling respondents who were enrolled in both 
Medicare and Medicaid for 12 months in each calendar year of participation. The MCBS is a 
nationally representative panel survey that selects beneficiaries from Medicare enrollment 
records according to a multi-stage sampling plan.  The Cost and Use subsample has a three-year 
rotating panel design with a portion of the sample replenished each year. Survey data include a 
wide range of information based on both administrative records and self-reports, including 
demographics, health status, insurance, services utilization, prescription fills, and payments from 
all sources.  We required that respondents in years 2000-2005 (pre-Part D) have at least one 
prescription with a payment from Medicaid to be included in our sample for a given year.  In 
2006 and 2007 (post-Part D), we required respondents to have at least one prescription with a 
payment from a Medicare Part D plan.  
We determined state Medicaid pharmacy benefits policies, including caps on fills per 
month, based on the annual report of the National Pharmaceutical Council in 2005.
15
 We found 
that 21 states (including the District of Columbia) reported having caps and 30 states reported no 
caps. The specific details of the caps varied, ranging from limits of 3 to 15 per month for all 
prescriptions, to separate limits for branded and other drugs, to a monetary cap rather than a cap 
on the number of prescriptions.  We excluded sample respondents living in Tennessee and 
Illinois because both states implemented a drug cap during 2005.  We disregarded changes in cap 
policies (i.e., addition or removal of caps) that may have occurred between 2000 and 2004, and 
30
  
state differences in other cost-containment policies. For more details about Medicaid pharmacy 
benefits, see Table 2.1. 
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Table 2.1.  Description of States with a Prescription Drug Cap Policy 
 
Sources:  Pharmaceutical Benefits Under State Medical Assistance Programs, 2005. National 
Pharmaceutical Council  
 
State Cap Brand Cap Monetary Cap Notes
Alabama 4
Arkansas 3 Also can receive extension of three more per month.
California 6 Some rxs are exempted 
Delaw are 15
District of Columbia $1,500 Prior Authorization override
Georgia
$2,999.99
Illinois 3
Kansas 5
4 3
      a. Acute infection or infestation;   
      c. Cancer;                                             
      e. Chronic pain;                                     
      g. Cystic f ibrosis;                                 
      i. Diabetes;                                          
      k. End stage renal disease;             
      m. Hemophilia;                                     
      o. Hyperlipidemia;                              
      q. Major depression;                          
      s. Organ transplant; or                       
    or
b. Bipolar disorder;   
d. Cardiac rhythm disorder;   
f . CHD or CVD
h. Dementia;
j. End stage lung disease; 
l. Epilepsy; 
n. HIV or AIDS    
p. Hypertension;
r. Metabolic syndrome;
t. Psychotic disorder; 
Louisiana 8
Maine 5
Mississippi 5 2 Can apply for 2 additional per month
New  York 3.6 43 rxs annually. Overide process.
North Carolina 6
Oklahoma 6 3
Pennsylvania 6
South Carolina 4
Override up to 7 total rx in a month is 
allow ed based on a list of conditions. 
Including:
♦ Acute sickle cell disease 
♦ Behavioral health disorder 
♦ Cancer  
♦ Cardiac disease (including high 
cholesterol) 
♦ Diabetes 
♦ End stage lung disease 
♦ End stage renal disease  
♦ HIV/AIDS 
♦ Hypertension (i.e., high 
blood pressure)  
♦ Life threatening illness (not 
otherw ise specif ied)  
♦ Organ transplant 
♦ Terminal stage of an illness  
Tennessee 5 2 Cap inplemented in mid-2005, so excluded from study
Texas 3
Utah 7 Review  w hen filling more than 7 in a month
Washington 5 Review  of pharmacist w hen requesting 5th brand rx w ithin month
Kentucky
3 brand cap (w hen no generic equivalent available). 
Many rx categories excluded 
1. For any of the follow ing conditions:
2. As part of:
      a. Acute therapy for migraine headache or acute pain; or
      b. Suppressive therapy for thyroid cancer.
>$2,999.99 requires an override. 
>$9,999.99 requires paper claim and a copy of the prescription.
Did not go into effect until October 2005. Over 65 excluded, no cap on 
generics and certain drug categories including chemotherapy, 
anticonvulsants, and antipsychotics.
32
  
 
Study variables 
Our outcome measures were mean annual self-reported prescription drug fills and out-of- 
pocket drug costs.  Demographic characteristics of interest were age and gender (from 
enrollment files), and race and education (self-reported). All drug costs were converted to 2007 
US dollars using the consumer price index.
16
  
Statistical Analyses 
For the full dually-enrolled study sample and separately for the two subgroups defined by 
state cap policies, we examined the survey-weighted characteristics in all study years (2000-
2007) to check for discontinuities over time.  We calculated mean annual fills per person and 
OOP drug costs per person with 95% confidence intervals, applying annual cross-sectional 
survey weights supplied by the MCBS as well as our own standardizing weights based on the 
characteristics of the two subgroups, separately, in 2007.  
To model changes in drug utilization after Part D, we constructed time-series regression 
models on the pre-Part D data (2000-2005), establishing a baseline intercept and trend for each 
stratum of states.  We then used parametric bootstrapping techniques previously used to evaluate 
the study outcomes in a different study of the MCBS population.
17
  We conducted 10,000 
simulations, sub-setting the pre-Part D annual population means to estimate predicted outcome 
values in 2007, with 95% confidence intervals, assuming no transition to Part D.  We compared 
these predicted values to observed outcomes in 2007 to evaluate whether we could be 95% 
confident that they were different, while controlling for minor changes in demographic 
characteristics.  We further compared the differences in predicted and observed values between 
the two study groups using a difference-in-difference approach.  Our primary analysis focused on 
2007, because 2006 was a transitional year.  However, we also compared predicted and observed 
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values for 2006 in a sensitivity analysis.  We used SAS software, version 9.2 (SAS institute, Inc., 
Cary, North Carolina); this study was approved by the Human Subjects Committee of Harvard 
Pilgrim Health Care. 
Results 
 The demographic characteristics of the study population in 2000, 2005, 2006, and 2007 
are described in Table 2.2. Population characteristics were fairly stable over time; though there 
were slight shifts in age and education level over time in the states with caps, our statistical 
models accounted for these shifts.   
Table 2.2  Demographic Characteristics of Community- dwelling Medicare and Medicaid Dual 
Beneficiaries, 2000, 2005, 2006, and 2007 
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2000 to 2007. 
Survey estimates re-weighted to represent the national Medicare/ Medicaid duals population. 
1
The population under 65 is assumed to have qualified for Medicare via the disability 
entitlement. 
2
The Other Race category includes Black, Other, Asian, Hispanic, and North American Native. 
  
% (95% Confidence Interval)
Characteristics 2000 (n=968) 2005 (n=1,039) 2006 (n=1,079) 2007 (n=946)
No caps 311 401 434 359
Caps 657 638 645 587
No caps
Under 65
1
45.9% (41.5-50.2) 44.5% (38.6-50.4) 42.7% (37.3-48.0) 43.4% (37.8-49.0)
65+ 54.1% (49.8-58.5) 55.5% (49.6-61.4) 57.3% (52.0-62.7) 56.6% (51.0-62.2)
Sex (female) 61.1% (55.1-67.1) 65.2% (59.4-71.0) 64.3% (53.3-69.3) 59.6% (53.6-65.6)
Race (white) 72.2% (67.0-77.3) 71.4% (65.4-77.4) 72.7% (67.4-78.1) 67.9% (62.1-73.8)
Race (other)
2
27.8% (22.7-33.0) 28.6% (22.6-34.6) 27.3% (21.9-32.6) 32.1% (26.2-37.9)
No high school diploma 62.1% (55.0-69.2) 49.8% (43.2-56.3) 52.9% (47.3-58.6) 53.5% (47.3-59.8)
At least high school diploma 37.9% (30.8-45.0) 50.2% (43.7-56.8) 47.1% (41.4-52.7) 46.5% (40.2-52.7)
Caps
Under 65 37.3% (32.6-42.0) 41.3% (36.1-46.6) 38.7% (34.3-43.2) 41.5% (35.8-47.2)
65+ 62.7% (58.0-67.4) 58.7% (53.4-63.9) 61.3% (56.8-65.7) 58.5% (52.8-64.2)
Sex (female) 67.7% (63.8-71.7) 63.9% (60.3-67.4) 65.2% (61.2-69.1) 64.7% (61.0-68.4)
Race (white) 56.1% (50.3-62.0) 55.6% (48.6-62.5) 55.3% (48.1-62.4) 54.7% (47.4-62.0)
Race (other) 43.9% (38.0-49.7) 44.4% (37.5-51.4) 44.7% (37.6-51.9) 45.3% (38.0-52.6)
No high school diploma 67.4% (61.3-73.4) 56.4% (52.0-60.9) 60.4% (56.1-64.7) 57.5% (53.0-62.1)
At least high school diploma 32.6% (26.6-38.7) 43.6% (39.1-48.0) 39.6% (35.3-43.9) 42.5% (37.9-47.0)
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Figure 2.1 shows mean annual drug fills for dual enrollees in the two groups of states 
defined by the presence or absence of a drug cap.  In the no-cap states, drug utilization increased 
during the baseline from an average of 48.4 fills in 2000 to 56.8 in 2005, and then rose to 65.2 
fills in 2007.  In the states with drug caps, average fills increased from 38.5 to 48.4 during the 
baseline years, and then rose to 63.9 fills in 2007.   
Figure 2.1.  Annual Average Prescription Drug Fills for Dual Beneficiaries by State Medicaid 
Program Cap Status 
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2000 to 2007. 
Note: Estimates weighted to represent the national Medicare/ Medicaid duals population. 
Individuals residing in states with a monthly limit on the number of prescriptions covered by 
Medicaid in 2005 were assigned to the Caps group.  
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 Table 2.3 displays estimated changes in annual fills after Part D based on time-series 
modeling of the six baseline years and our bootstrapped estimates of predicted values in 2007.  
In the states with no caps, we found the observed average in 2007 was 4.4 (95% CI: 0.3-8.2) fills 
higher than expected.  In the states with caps, the 2007 observed average was 10.5 (95% CI: 7.7-
13.3) fills above the predicted level.  These results lead to a difference-in-difference estimate of 
6.2 fills (95% CI: 6.17, 6.21) between the cap and no cap groups (data not shown). 
 Table 2.3 also presents observed and predicted values for average annual out-of-pocket 
drugs costs.  We found that, in the no-cap states, observed OOP costs per person were $143.22 
(95% CI: -$239.30, -$45.90) lower than predicted in 2007.  In states with caps, we found that 
observed OOP costs per person were $40.71 (95% CI: -$66.1, -$15.90) lower in 2007 than 
predicted.    
Table 2.3. Estimated Changes in Average Annual Prescription Drug Fills, and Out-of-Pocket 
Drug Costs (OOP) After Part D Implementation among Community-Dwelling Medicare/ 
Medicaid Dual Beneficiaries by Medicaid Pharmacy Benefit Cap Status 
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2000 to 2007. 
 
1
 Predicted using autoregressive models based on 2000 to 2005 historical trends. Confidence 
intervals were constructed by creating 10,000 simulated values per outcome using the bootstrap 
method. 
 
 
 
Outcome Measures 2000 2005 2006 2007 2006 2007
Average number of fills
No caps 48.8 56.8 61.4 63.3 57.9 (54.7-61.0) 58.9 (55.0-63.0) 3.5 (0.4-6.7) 4.4 (0.3-8.2)
Caps 38.5 48.4 56.8 63.9 53.5 (50.7-56.2) 53.5 (48.6-58.3) 5.5 (3.1-8.0) 10.5 (7.7-13.3)
Average OOP drug costs
No caps $155 $288 $184 $171 $285 (189-378) $315 (217-411) -$101 (-194- -5) -$143 (-239- -46)
Caps $152 $191 $166 $181 $211 (189-234) $221 (197-247) -$46 (-68- -23) -$41 (-66- -16)
Observed
Predicted
1
Mean (95% Confidence Interval)
Difference between 
Observed and Predicted (95% Confidence 
Interval)
2006 2007
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Discussion 
 Before 2006, dually-enrolled Medicare and Medicaid beneficiaries received pharmacy 
coverage through their state Medicaid programs, and this coverage varied in generosity across 
states. Our study found that both study subgroups experienced increases in fills per person, as 
well as reductions in patient drug spending, after transitioning to Medicare Part D plans.   The 
point estimate for the increase in fills in the cap states was substantially larger than that found in 
the no-cap states.  These findings are consistent with our a priori hypothesis that dual 
beneficiaries would experience different impacts depending on the state in which they resided.  
We expected larger increases in medication use in capped states based on earlier research 
establishing that removal of Medicaid drug caps in the 1980’s led to marked increases in 
utilization of medicines.
14
  
Our results suggest important geographic disparities in access to medication prior to Part 
D.  These disparities and problems of access remain highly relevant today, as many states 
continue to employ caps to control the costs of healthcare for vulnerable Medicaid beneficiaries, 
most of whom do not have Medicare eligibility.  After Part D, some convergence in terms of 
levels of medication use appears to have occurred for the dual enrollees.      
A priori, we had no hypothesis about a differential impact of transitioning to Part D on 
out-of-pocket spending, because of the variety and complexity of other cost-containment policies 
in place in both state Medicaid programs and PDPs.  These policies included copayment amounts 
(Medicaid), copayment enforcement (Medicaid), and prior authorization requirements (Medicaid 
and PDPs).  Moreover, the lack of available data on these other cost-containment policies meant 
it was not possible to control for them in our analyses.  We know that prior to Part D, Medicaid 
could not deny prescriptions for beneficiaries if they could not afford to pay,
18
 but once the dual 
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eligibles transitioned to Part D, they were required to meet the copayment in order to obtain their 
prescriptions.  We elected to focus this paper on pharmacy benefit caps because there is relative 
clarity on what policies were in place prior to Part D, as well as prior evidence of particularly 
strong effects.  We found significant drops in OOP spending after Part D, in both cap and no-cap 
states.  Together, our results indicating increased fills and lowered costs suggest substantial 
improvements in access to treatment and reductions in the financial burden of treatment for dual 
enrollees after Part D. 
Our study fills an important gap in the literature on the effects of Part D, on dual 
enrollees in particular, and on geographic variations in impact.  Moreover, our study has the 
advantage of using self-reports of drug use and spending.  The bulk of the existing empirical 
evidence on Part D is based on claims data alone.  These studies cannot account for purely out-
of-pocket purchase or free samples (which the MCBS does), and copayment amounts in claims 
for dual enrollees may not reflect uneven enforcement of these copayment policies. 
This study has several limitations.  There were changes over time in the relative sizes of 
the two subgroup samples, in the composition of individual states making up the subgroups, as 
well as secular changes in demographic characteristics.  These changes could potentially 
compromise the comparisons.  Consequently, we adjusted for these changes by using weights 
that standardized the population to match the demographic composition of the 2007 cohort.  All 
outcomes were self-reported and might be at risk for recall bias.  However, previous validations 
of the self-reported drug use measure in 1999 and 2006 suggested undercounting of medications 
by 17.7 and 16.8 percent, respectively, of the samples
17,19
 which suggests the self-reported drug 
measure is likely consistent across the study period.  Also, because of the small samples, we 
were not able to distinguish further among the range of cap policies seen in the group of cap 
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states.  Since we included both highly restrictive and less restrictive cap states in this group, our 
results regarding the differential impact of Part D for duals coming from capped benefits can be 
considered conservative.  It would be informative to investigate how the coverage transition 
affected specific drug choices for beneficiaries with specific chronic illnesses with high 
medication needs, but we did not have sufficient sample size to address these questions. 
 Our study found that transition from Medicaid pharmacy benefits to PDPs among dually 
enrolled beneficiaries coincided with substantial increases in utilization and decreased out-of-
pocket spending.  Notably, we found substantially larger point estimates for the increased 
utilization among states with capped Medicaid benefits.  Further analyses are warranted focusing 
on other changes in cost-containment strategies (whether implemented by state Medicaid or 
specific PDPs), and using larger datasets to investigate effects among more specific clinical 
populations.  Such analyses would create a more detailed picture of the gains and set-backs that 
may have occurred.  There is some evidence that utilization management policies have become 
more stringent over time (e.g., increases in copayment amounts).
13
 Continued research to 
monitor utilization and spending patterns over time will be important to evaluate the impact of 
changes to utilization management policies.  This kind of knowledge will be critical to guiding 
future adjustments to pharmacy coverage arrangements for this population. 
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Abstract 
Objective: We evaluated how Medicare Part D implementation affected the prevalence of antidepressant 
medication use and treatment intensity among nonelderly disabled and elderly Medicare beneficiaries. 
Methods: Using the Medicare Current Beneficiary Survey (MCBS) from 2001 to 2007, we identified 
annual cohorts of community-dwelling respondents and stratified the study population into nonelderly 
disabled and elderly subgroups. Outcome measures were annual prevalence of antidepressant treatment 
and treatment intensity (average number of fills among those with any fills in a year).  We constructed 
time-series regression models based on pre-Part D data (2001-2005) to estimate predicted values in 2007 
for comparison with observed outcomes. We also estimated effects among subgroups of beneficiaries who 
self-reported depressive symptoms.     
Results:  Among both elderly beneficiaries and the nonelderly disabled overall, we detected no change in 
antidepressant treatment prevalence attributable to Part D.  However, in both groups, those receiving any 
antidepressant treatment experienced a higher than expected number of fills in 2007 (a relative difference 
of 11.9% (95% CI: 6.8-17.6%) and 11.1% (95% CI: 5.8-17.0%) for the elderly and non-elderly disabled, 
respectively).  In subgroup analyses, we found that non-elderly disabled beneficiaries reporting symptoms 
of depression had no increases in either prevalence of treatment or intensity of treatment. 
Conclusions: Our study suggests that Part D had no effect on whether Medicare beneficiaries accessed 
any antidepressant treatment in a year.  Treated patients, however, received more intense treatment after 
Part D.  Potential explanations of these findings include the presence of patient-level barriers (e.g., 
inadequate understanding of Part D) as well as insurance administrative barriers to treatment initiation 
under Part D.  Our findings suggest that both elderly and nonelderly beneficiaries still have difficulties 
overcoming obstacles to necessary psychotropic therapies, even in a context of expanded coverage. 
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Introduction 
In 2006, the Medicare Part D drug benefit became available, enabling many Medicare 
beneficiaries to gain such coverage.  Policymakers' expectation in creating Part D was that it 
would improve access to medications for Medicare beneficiaries, especially those who 
previously had lacked prescription drug coverage.
1,2
 While research has shown the 
implementation of Part D to be associated with increased utilization of medications among 
beneficiaries overall,
3-5
 more focused evaluations of Part D impacts are needed for specific types 
of medications, such as antidepressants.  Antidepressant medications are an effective and 
recommended treatment modality for depression.
6,7
  Depression affects 10% to 18% of Medicare 
Beneficiaries and is associated with higher total health care spending compared with 
beneficiaries who do not suffer from depression.
8-10  Those suffering from depression are more 
likely to have other chronic illnesses, such as diabetes and cardiovascular disease, which can also 
be affected by appropriate treatment of depression.
11,12
   Therefore, antidepressant medications 
are an important component of treatment for this population. 
Private prescription drug plans compete to sell coverage to Medicare beneficiaries under 
the Part D program.  Before Medicare Part D went into effect, there were widespread concerns 
about whether beneficiaries would be able to obtain appropriate antidepressants from these plans.  
The worry was that plans might limit the drugs on their formularies so as to discourage people 
with depression from enrolling in their plan, as people with depression frequently have higher 
total prescription drug costs.  To prevent this outcome, the regulations for plans participating in 
Part D require coverage of at least one drug in every therapeutic category and require risk 
adjustments to be applied to reimbursement rates so that the risks of higher than anticipated drug 
expenditures are limited.
13-15
 Furthermore, antidepressants were included in a special category of 
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drugs for which all chemical entities had to be covered.
16
 Despite these protections, concerns 
remained that plans had too much flexibility in benefit design, allowing plan designers to make 
the plans appear less attractive to individuals with mental illness in order to avoid high-cost 
enrollees.  Although the plans might meet formulary requirements, in order to steer higher- cost 
beneficiaries away, they might offer coverage only for less frequently prescribed formulations or 
might erect other administrative barriers such as step therapy and prior authorization 
requirements.
13
   
Past research has consistently documented distinct differences between the elderly and 
nonelderly disabled Medicare populations.
17-19
  The disabled are heavy medication users and 
tend to use more psychotropic medications than the elderly.
18
   Historically, nonelderly disabled, 
who are more likely to have low income and poor health status, have encountered significantly 
more access problems and cost-related barriers to care than the elderly.
18
  Therefore, it is 
possible that, even with the expansion of drug coverage, the nonelderly disabled seeking 
treatment for depression would still have difficulty navigating the new insurance system and 
gaining access to antidepressant medications.  We know that a large proportion (approximately 
50%, compared with about 27% among the elderly) of the disabled population likely had drug 
coverage under Medicaid prior to Part D because they are dually eligible for Medicare and 
Medicaid.  Since state Medicaid drug insurance policies vary in benefit generosity, it's possible 
that some of these beneficiaries may not experience an improvement in access to medicines after 
Part D implementation because of new utilization management policies that may be in place.  For 
example, some state Medicaid programs don’t require any copayments, so the addition of a $3 
copayment requirement for filling a prescription among the dual nonelderly disabled may reduce 
the likelihood that a dually eligible beneficiary will get access to that medication.  Previous 
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research has found that copayments as low as $0.50 are associated with an immediate drop in 
medication utilization.
20
  Depending on their prior experience in Medicaid, the dually eligible 
beneficiaries may not experience improved access to medications after Part D went into effect. 
Recent research found that cost-related medication nonadherence (CRN) is much higher 
among those who report symptoms of depression, compared to those reporting no symptoms. 
8,21
  
Further, after Part D implementation, CRN for Medicare beneficiaries remained unchanged for 
those also reporting symptoms of depression, whereas CRN decreased substantially among those 
reporting no symptoms. Another study found that among Medicare beneficiaries reporting any 
type of nonadherence, antidepressants were among the most frequently unfilled prescription 
drugs.
22
   
In this study, we examine self-reported prevalence of treatment and treatment intensity 
with antidepressant medications among elderly and nonelderly disabled beneficiaries before and 
after Part D implementation.  We also evaluate a subset of beneficiaries reporting depressive 
symptoms.  We use time series models to estimate the impact of Part D on these outcomes while 
accounting for pre-existing trends.  
Methods 
Data and study population  
Using the Medicare Current Beneficiary Survey (MCBS) from 2001 to 2007, we 
identified annual cohorts of Medicare enrollees in the Cost and Use data files. The MCBS is a 
nationally representative survey that selects beneficiaries from Medicare enrollment records 
according to a multi-stage sampling plan.  The Cost and Use sample has a 3-year rotating design, 
with approximately one third of the sample panel replenished each year.  Survey data include a 
wide range of self-reported outcomes including demographics, health status and chronic illness, 
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health insurance, health services utilization, prescription drug fills, and payment amounts from 
all sources.  For our main study population we included only community-dwelling individuals 
who were enrolled in Medicare Parts A and B for 12 months in each calendar year of 
participation.   
For our supplemental analysis, we identified a subgroup of respondents who reported 
beneficiaries with depressive symptoms.  To identify this group we used two questions in the 
MCBS that address specific criteria in the Diagnostic and Statistical Manual of Mental 
Disorders:
23
 sadness and anhedonia, which have been established as strong indicators of 
depression.
24
  Based on previously published methods,
8,21
 respondents were assigned to 
“depressive” status during a given study year if they answered “all of the time” or “most of the 
time” to the survey question, “In the past 12 months, how much of the time did you feel sad, 
blue, or depressed?,” or “Yes” to the item, “In the past 12 months, have you had two weeks or 
more when you lost interest or pleasure in things you usually enjoyed?”.   
Study variables 
We have two outcome measures: total prevalence of antidepressant treatment (percentage 
of the population with any antidepressant fill in a year) and intensity of treatment (mean number 
of antidepressant fills among the population that received any fills in a year).  Demographic 
characteristics we describe for the elderly and nonelderly disabled subgroups were gender, race, 
education, and number of comorbidities. Although the MCBS began to include Part D event data 
(claims) in the 2006 Cost and Use file in addition to self-reported prescription drug events, we 
included only self-reported drug events in all sample years, so as to measure outcomes 
consistently over time.  Spending on medications was converted to 2007 US dollars using the 
consumer price index.
25
 Recognizing that nonelderly disabled and elderly Medicare beneficiaries 
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represent quite distinct populations in terms of healthcare utilization and various demographic 
and clinical characteristics,
26
 including prevalence of depression,
10
 we stratified our analyses 
accordingly.   
Statistical Analyses 
We examined demographic and health characteristics of the MCBS population, 
nonelderly and elderly, overall and with depressive symptoms, in all study years.
27,28
  We 
calculated the survey-weighted annual prevalence of antidepressant treatment and mean 
treatment intensity for each study cohort.  Annual cross-sectional survey-weights supplied by the 
MCBS were applied in all analyses. 
To estimate changes after Part D for each outcome and beneficiary group, we constructed 
time-series regression models based on the pre-Part D data (2001-2005).  Each model established 
a baseline intercept and trend and allowed us to calculate the expected value of outcomes in 
2007, had Medicare Part D not been implemented.  Using parametric bootstrapping techniques,
3
 
we then conducted 10,000 simulations per model to construct 95% confidence intervals around 
the predicted value. We compared these predicted values to observed values from the 2007 
survey data to determine whether the transition to Part D had an impact on outcomes.  Our 
primary analysis focused on 2007, because 2006 was a transitional year.  We also modeled 2006 
expected outcomes in a sensitivity analysis.  We controlled for changes in education over the 
study period of the different yearly cohorts by deriving and applying standardized weights from 
stratum-level characteristics of the population in 2007.   
We used SAS software, version 9.3 (SAS institute, Inc., Cary, North Carolina), to 
conduct these analyses. This study was approved by the Human Subjects Committee of Harvard 
Pilgrim Health Care.  
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Results 
Demographic characteristics of the study population for a selection of study years in 
2001, 2003, 2005, and 2007 are presented in Table 3.1. Population characteristics were fairly 
stable over time; even though the educational attainment rose over the years, our statistical 
models accounted for these gradual shifts.  Rates of self-reported depression were remarkably 
stable, although with a slight downward trend.  Self-reported symptoms of depression were 
associated with disability status and higher burden of comorbid illness.  For example, among the 
elderly in 2007, 53% of individuals reported 3 or more non-psychiatric chronic conditions, but 
among the subgroup with depressive symptoms, 67% reported 3 or more. 
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Table. 3.1 Demographic and Health Characteristics of Community-dwelling Medicare 
Beneficiaries, 2001, 2003, 2005, and 2007. 
  
Study Population
Under 65, overall 1,341 (100%) 1,344 (100%) 1,347 (100%) 1,383 (100%)
Depressive symptoms
1
557 (42%) 553 (41%) 550 (41%) 553 (40%)
65 or older, overall 7,712 (100%) 7,634 (100%) 7,328 (100%) 7,401 (100%)
Depressive symptoms 1,185 (15%) 989 (13%) 873 (12%) 870 (12%)
Sex (female)
Under 65, overall 45.6% (43.0-48.2) 45.9% (42.8-49.0) 48.0% (44.8-51.2) 49.4% (45.8-53.0)
Depressive symptoms 49.7% (44.9-54.5) 50.1% (45.5-54.7) 52.0% (47.3-56.7) 52.0% (46.6-57.4)
65 or older, overall 59.9% (58.8-60.9) 58.5% (57.4-59.5) 58.2% (57.1-59.4) 57.4% (56.1-58.8)
Depressive symptoms 65.7% (63.0-68.3) 63.4% (60.7-66.1) 65.0% (61.6-68.4) 64.7% (61.3-68.1)
Race
Under 65, overall
White 76.2% (73.0-79.4) 71.4% (67.0-75.9) 74.5% (70.0-79.0) 72.7% (68.9-76.5)
Other 23.8% (20.6-27.0) 28.6% (24.1-33.0) 25.5% (21.0-30.0) 27.3% (23.5-31.1)
Depressive symptoms
White 79.3% (75.7-82.9) 73.1% (67.1-79.1) 77.4% (71.4-83.4) 75.7% (71.4-80.0)
Other 20.7% (17.1-24.3) 26.9% (20.9-32.9) 22.6% (16.6-28.6) 24.3% (20.0-28.6)
65 or older, overall
White 87.8% (86.6-80.1) 87.4% (11.3-13.9) 87.2% (85.6-88.8) 87.7% (86.2-89.1)
Other 12.2% (10.9-13.4) 87.4% (86.1-88.7) 12.8% (11.2-14.4) 12.3% (10.9-13.8)
Depressive symptoms
White 86.4% (83.9-88.9) 86.3% (83.5-89.1) 86.3% (83.6-89.1) 85.8% (83.0-88.5)
Other 13.6% (11.1-16.1) 13.7% (10.9-16.5) 13.7% (10.9-16.4) 14.2% (11.5-17.0)
% (95% Confidence Interval)
2001 2003 2005 2007
49
  
 
 
 
 Table 3.1 (continued).  Demographic and Health Characteristics of Community-dwelling Medicare 
Beneficiaries, 2001, 2003, 2005, and 2007. 
 
Source: Medicare Current Beneficiary Survey Cost and Use data 2001, 2003, 2005, and 2007. 
 
Note: All percentages estimated based on MCBS survey weights.  
 
1
Self report of symptoms of depression based on response to two MCBS survey questions 
described in Methods section 
2
Morbidity categories included cardiac disease, hypertension, cerebrovascular disease, lung 
disease, cancer, diabetes mellitus, arthritis, psychiatric disorder or depression, dementia, and 
other neurological conditions.
Education
Under 65, overall
No high school diploma 36.3% (33.4-39.1) 33.6% (30.8-36.4) 30.5% (28.0-33.1) 29.0% (26.4-31.7)
High school diploma or higher 63.7% (60.9-66.6) 66.4% (63.6-69.2) 69.5% (66.9-72.0) 71.0% (68.3-73.6)
Depressive symptoms
No high school diploma 34.2% (29.8-38.6) 32.7% (28.5-37.0) 32.6% (28.5-36.7) 29.4% (25.2-33.6)
High school diploma or higher 65.8% (61.4-70.2) 67.3% (63.0-71.5) 67.4% (63.3-71.5) 70.6% (66.4-74.8)
65 or older, overall
No high school diploma 31.5% (29.7-33.2) 29.3% (27.8-30.8) 27.2% (25.6-28.8) 25.6% (24.0-27.3)
High school diploma or higher 68.5% (66.7-70.3) 70.7% (69.2-72.2) 72.8% (71.2-74.4) 74.4% (72.7-76.0)
Depressive symptoms
No high school diploma 41.2% (38.3-44.1) 39.6% (36.0-43.2) 41.7% (37.7-45.7) 36.0% (32.6-39.4)
High school diploma or higher 58.8% (55.9-61.7) 60.4% (56.8-64.0) 58.3% (54.3-62.3) 64.0% (60.6-67.4)
Comorbidities
2
Under 65, overall
White0-2  41.1% (37.2-45.1) 39.0% (35.7-42.3) 37.0% (33.6-40.4) 36.2% (32.8-39.7)
Other3+ 58.8% (54.8-63.0) 61.0% (57.7-64.3) 62.8% (59.4-66.2) 62.8% (59.8-65.9)
Depressive symptoms
White0-2  30.9% (25.7-36.0) 30.5% (26.3-34.7) 25.2% (21.3-29.0) 29.7% (24.4-35.0)
Other3+ 69.1% (64.0-74.3) 69.5% (65.3-73.7) 74.4% (70.5-78.4) 70.2% (64.9-75.5)
 65 or older, overall
White0-2  49.1% (47.6-50.6) 47.6% (46.3-48.9) 46.2% (44.9-47.4) 44.7% (43.2-46.2)
Other3+ 50.8% (49.2-52.3) 52.4% 51.0-53.7) 53.5% (52.2-54.8) 54.8% (53.3-56.3)
Depressive symptoms
White0-2  33.0% (30.1-36.0) 28.7% (25.5-31.9) 30.2% (26.7-33.7) 27.1% (24.1-30.0)
Other3+ 67.0% (64.0-69.9) 71.3% (68.1-74.5) 69.4% (66.0-72.9) 72.6% (70.0-75.5)
% (95% Confidence Interval)
2001 2003 2005 2007
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Changes in Antidepressant Treatment among Elderly Beneficiaries 
 
Figure 3.1a displays annual prevalence of antidepressant treatment for elderly Medicare 
beneficiaries overall and for the subgroup reporting depressive symptoms.  The rate of treatment 
for depression among the entire elderly population increased from 11.2% to 13.9% during the 
baseline period (2001-2005) and reached 14.8% in 2007.  The average number of antidepressant 
fills per year among elderly beneficiaries treated for depression increased from 5.9 in 2001 to 6.4 
in 2005 (Figure 3.1b).  By 2007, average treatment intensity had reached 7.1.  Among the subset 
of elderly with depressive symptoms, treatment prevalence increased from 25.8% to 29.5% 
during the baseline and then increased to 36.0% in 2007.  The treatment intensity for this 
beneficiary group increased from 5.7 fills in 2001 to 7.0 fills in 2005, and then increased to 7.8 
fills in 2007.   
Table 3.2 displays estimated changes in outcomes for elderly beneficiaries after Part D 
based on our time-series modeling of the five baseline years and bootstrapped estimates of 
predicted values in 2007.  Among the elderly overall, which was the largest of our study cohorts, 
we found no significant change in the prevalence of treatment attributable to Part D.  However, 
the relative difference in predicted versus observed number of fills among the treated in 2007 
was 11.9% (95% CI: 6.8-17.6%).  Among the elderly with depressive symptoms, both treatment 
prevalence and treatment intensity were significantly higher in 2007 than predicted based on 
baseline data (relative differences of 11.8% (95% CI: 1.4-25.0%) and 7.2% (95% CI: 1.4-
13.9%), respectively). 
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Figure 3.1a.  Rate of Antidepressant Treatment Among Elderly Medicare Beneficiaries and the 
Subgroup Reporting Depressive Symptoms  
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2001 to 2007. 
Note: Estimates weighted to represent the national Medicare population.  
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Figure 3.1b.  Average antidepressant Drug Fills per Year Among the Treated Elderly Medicare 
Beneficiaries and the Subgroup Reporting Depressive Symptoms  
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2001 to 2007. 
Note: Estimates weighted to represent the national Medicare population.  
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Changes in Antidepressant Treatment among Nonelderly Disabled Beneficiaries 
Figure 3.2a shows the prevalence of antidepressant treatment for the subgroup of 
nonelderly disabled beneficiaries overall and for the subgroup reporting symptoms of depression.  
Treatment prevalence was just over 30% between 2001 and 2003, then increased from 32.0% to 
36.2% in 2004, and remained stable thereafter.  Antidepressant treatment intensity (Figure 3.2b) 
was fairly stable during the baseline among the disabled overall (8.7 fills per year in 2001 and 
8.8 in 2005), and then it increased to 10.2 fills by 2007.  Among the subgroup with symptoms, 
treatment prevalence increased from 43.8% to 55.2% during the baseline period, apparently 
including an uptick between 2003 and 2004 similar to the increase in treatment prevalence 
among all the nonelderly disabled.  After Part D was in effect, however, there was a notable 
decrease in prevalence to 49.9% among those with symptoms.   
Table 3.3 displays estimated changes in outcomes for nonelderly disabled beneficiaries 
after Part D based on our time-series modeling of the five baseline years and bootstrapped 
estimates of predicted values in 2007.  Because of the discontinuities (annual relative change of 
10% or more) in the baseline trends for treatment prevalence among the two disabled groups, the 
linear regression models should be interpreted with caution because we analyzed the series based 
on an assumption of a linear trend.  For the disabled overall, the time series and bootstrap 
approach predicts a significant relative decrease of 9.1% in treatment prevalence after Part D was 
in effect (95% CI: -14.8--2.4). However, the relative difference in predicted versus observed 
number of fills among the treated in 2007 was 11.1% (95% CI: 5.8 - 17.0%).  Among the 
disabled reporting depressive symptoms, the relative difference between the predicted results 
from our statistical model and the observed data indicate a 17.9% relative decrease in 
antidepressant treatment prevalence (95% CI -24.1- -10.5).  No significant change in treatment 
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intensity was detected for this subgroup in 2007 using our statistical modeling approach (relative 
difference -3.2%; 95% CI: -11.8 - 7.4%).   
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Figure 3.2a. Rate of Antidepressant Treatment Among Disabled (under age 65) Medicare 
Beneficiaries and the Subgroup Reporting Depressive Symptoms  
Source: Medicare Current Beneficiary Survey Cost and Use data from 2001 to 2007. 
Note: Estimates weighted to represent the national Medicare population. 
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Figure 3.2b. Average antidepressant Drug Fills per Year Among the Treated Disabled Medicare 
Beneficiaries and the Subgroup Reporting Depressive Symptoms 
 
Source: Medicare Current Beneficiary Survey Cost and Use data from 2001 to 2007. 
Note: Estimates weighted to represent the national Medicare population.  
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Discussion 
Our analyses found no statistically significant change in the prevalence of antidepressant 
treatment attributable to Part D among elderly Medicare beneficiaries.  However, elderly 
beneficiaries who did use an antidepressant medication were likely to receive more 
antidepressant prescription fills after Part D.  This suggests that once they surmounted initial 
barriers to access (such as clinician prescribing and coverage restrictions), they received 
prescription drug treatment for a longer period after Part D.  Among nonelderly disabled 
beneficiaries, our findings were similar.  We did not observe any change in terms of the 
prevalence of treatment initiation among the disabled, but there was a significant increase in 
treatment intensity for those who were treated.  These main findings raise several questions 
about the effectiveness of Part D in increasing access to medications for vulnerable populations.   
It is possible special protections around antidepressants under Part D were insufficient to ensure 
access to this drug class, and Part D plans erected excessively high barriers to treatment.   
It is not possible to state precisely what prevalence of treatment might be termed the 
“appropriate” level for the population of Medicare beneficiaries.  Nor is it possible, with the 
MCBS data, to know the extent to which treatment that was received was appropriate.  However, 
we know from extensive research published elsewhere
29,30
 that depression is seriously 
undertreated in the US, particularly among elderly and chronically ill populations.  So we might 
expect that with a well-documented drug coverage expansion such as Part D, significant 
increases in use would occur.  It may be that other factors, distinct from the changes in coverage, 
inhibited increases in use.  For example, physicians, particularly those caring for older, sicker 
patients, may be prioritizing other conditions in the limited time available during visits.  Patients 
are often reluctant to discuss stigmatized mental illnesses.  A widely publicized FDA black box 
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warning on SSRI medications in late 2004
31
 is known to have led to the flattening or reversal of 
rising antidepressant use rates in other US populations.
32-34
  
 We focused our main analyses on the Medicare beneficiary population stratified by 
elderly versus nonelderly, regardless of depression status.  To best ensure that these analyses 
were clinically relevant, we restricted our list of antidepressant agents to those medications that 
are usually used exclusively for the treatment of depression.  We excluded medications such as 
bupropion and nortriptyline which are often prescribed for other purposes.  In sensitivity 
analyses not shown here, we repeated all analyses using the broader list of antidepressant agents, 
and the results were nearly identical.   
 In a further attempt to isolate treatment of true depression, we took advantage of clinical 
information available in the MCBS to conduct secondary analyses limited to persons reporting 
depressive symptoms.  Using the MCBS measures of sadness and anhedonia represents a widely-
validated
35
 approach for identifying people with depression, and these measures appear strongly 
correlated with other characteristics known to be associated with depression and are stable over 
time.  Our supplemental analyses evaluating changes after Part D among subgroups reporting 
these depressive symptoms offered a somewhat more complicated picture than our overall 
population analyses.  Among the elderly, our findings suggested that patients reporting 
depressive symptoms were more likely than beneficiaries overall to experience an increase rate 
of treatment with antidepressants after Part D.  By contrast, among the nonelderly disabled, those 
who reported depressive symptoms appeared to have experienced decreased prevalence of 
treatment and no change in treatment intensity after Part D. We note that the baseline data were 
somewhat unstable in this smaller group so we must interpret these changes with caution.   
61
  
 
 
 
  Our findings are consistent with our previous work showing special vulnerability among 
nonelderly disabled and depressed Medicare beneficiaries who appeared to experience fewer or 
only delayed improvements in overall medication access after Part D when compared with the 
mainstream of beneficiaries.
3,8,21,36
 Previous research among beneficiaries diagnosed with 
depression
11
 found that prevalence of antidepressant use increased only among those enrolling in 
Part D who did not have drug coverage prior to Part D.   We did not limit our analyses to persons 
entering Part D without prior drug coverage because self-selection into Part D (generally by 
sicker persons)
37,38
 would invalidate any conclusions from such an analysis.  Our population-
wide analyses tend to dilute the effects of policies that affect only a portion of individuals 
(approximately 25% of beneficiaries gained drug coverage in 2006), but represent a valid and 
nationally representative longitudinal study, yielding appropriate estimates of actual changes. 
 There are several limitations in this study that merit mention.  Identifying a subgroup of 
patients with depression is challenging.  The MCBS includes linked claims data containing all 
diagnosis codes received through reimbursed health services, but we did not use these data to 
identify a depressed cohort, for two reasons.  First, other research
39
 has shown that depression is 
under-recorded in claims even when noticed in primary care, due in part to stigma or clinician 
uncertainty.  In addition, the MCBS claims data are only available in the MCBS for beneficiaries 
in fee-for-service Medicare.  In order to avoid selection biases that would result from increased 
beneficiary enrollment in managed care plans (Medicare Advantage), which cover prescription 
drugs, at the time of Part D implementation, we could not limit our study population to those in 
fee-for-services Medicare.  By foregoing the linked claims data on the MCBS we could include 
the Medicare Advantage enrollees.  Thus, we relied on the MCBS routine questions asking 
respondents about possible depressive symptoms rather than diagnosis codes to identify 
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beneficiaries with depression.  Sample size also presented a possible study limitation.  Some 
subgroups were smaller (e.g., average N for depressed disabled was 554 respondents per year), 
leading to less stable outcome series.  The timing of the interview questions about depressive 
symptoms (once each year in the fall) only partially corresponded with self-reported drug fills 
(prescriptions are filled throughout the year, reported in three interview sessions per year, and 
included in annual datasets without specific dates). Specifically, since the patient is asked to 
recall depressive symptoms in the prior 12 months when there is still time remaining in the 
current survey year, they may actually have experienced those symptoms in the prior year. Also, 
since there is no date associated with experiencing depressive symptoms, it is hard to know 
whether antidepressant use occurred before or after the report of symptoms.  Moreover, 
symptoms may indicate lack of treatment or unsuccessful treatment, while lack of symptoms 
may indicate lack of depression or its successful treatment.  Furthermore, we could not explain 
the apparent increase in antidepressant use among the nonelderly disabled between 2003 and 
2004.  We thoroughly examined rates and trends in the characteristics of this cohort, including 
geographic distribution and dual Medicaid enrollment, but found no evidence of change.  We 
note that generic fluoxetine first came on the market in 2001,
40
 but this did not coincide with the 
data anomaly.  Finally, we lack data on individual Part D plan formularies and utilization 
management strategies that might shed light on possible problems of antidepressant access for 
beneficiaries. Previous research suggests that only a minority of plans use prior authorization for 
antidepressant medications, but the level of restrictiveness of the authorization procedures is not 
clear.
16
   
Our evaluation found that both elderly and nonelderly Medicare beneficiaries experienced no 
change in the prevalence of antidepressant treatment after Part D.  However, among those 
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receiving antidepressants, the treatment intensity increased. Even though evidence suggests that 
prior authorization is not widely used in Part D plans,
16
 other utilization management strategies, 
such as step therapy and quantity limits are both common for the top brand name drugs in Part D 
plans.
41
 One study of employer insurance plans found that step therapy for antidepressant 
medications was associated with decreases in antidepressant days supplied and medication costs. 
However these reductions were accompanied by increases in mental health inpatient and 
emergency room utilization and costs that offset any savings.
42
  These findings suggest that 
limitations on access to antidepressant medications may not result in reductions in overall 
spending on and use of depression-related health services.  We found that although barriers to 
initial access may exist, once patients overcome those barriers they may be more likely to 
maintain their treatment after Part D was implemented.  We conclude that Part D implementation 
did not effectively reduce barriers to initiating treatment for depression.  
Further research investigating possible changes in utilization of other health services related 
to depression may also provide insight into shifts in care giving patterns in this population.   An 
evaluation of the impacts of Part D on receipt of guideline concordant care would provide more 
understanding of our results and the impact of Part D on quality of treatment for patients with 
depression.  Research that includes information about utilization management procedures will be 
important so that we can fully understand how Part D has changed access to specific 
medications. This knowledge will guide future policy safeguards meant to protect vulnerable 
subpopulations from unintended consequences of general policy changes.  
64
  
 
 
 
References 
1. KFF. Medicare and Prescription Drugs Fact Sheet: 2003. Henry J. Kaiser Family Foundation;2003. 
2. KFF. Medicare and Prescription Drugs Fact Sheet: 2006. Henry J. Kaiser Family Foundation;2006. 
3. Briesacher B, Zhao Y, Madden J, et al. Medicare Part D and Changes in Prescription Drug Use and Cost 
Burden National Estimates for the Medicare Population, 2000 to 2007. Medical Care. 2011;49(9):834-
841. 
4. Yin W, Basu A, Zhang J, Rabbani A, Meltzer D, Alexander G. The effect of the Medicare Part D 
prescription benefit on drug utilization and expenditures. Annals of Internal Medicine. 2008;148(3):169-
177. 
5. Lichtenberg F, Sun S. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff 
(Millwood). 2007;26(6):1735-1744. 
6. Health NCCfM. Depression. The Treatment and Management of Depression in Adults. In: (NICE) 
LUNIfHaCE, ed2009. 
7. NIMH. Depression. In: Health NIoM, ed2011. 
8. Zivin K, Madden J, Graves A, Zhang F, Soumerai S. Cost-Related Medication Nonadherence Among 
Beneficiaries With Depression Following Medicare Part D. Am j Geriatr Psychiatry. 2009;17:1068-1076. 
9. Unutzer J, Schoenbaum M, Katon W, et al. Healthcare Costs Associated with Depression in Medically Ill 
Fee-for-Service Medicare Participants. J Am Geriatr Soc. 2009;57:506-510. 
10. Stuart B, Simoni-Wastila L, Zuckerman I, et al. Medication Use by Aged and Disabled Medicare 
Beneficiaries Across the Spectrum of Morbidity University of Maryland School of Pharmacy;2007. 
11. Donohue J, Zhang Y, Men A, et al. Impact of Medicare Part D on Antidepressant Treatment, Medication 
Choice, and Adherence Among Older Adults With Depression. Am j Geriatr Psychiatry. 2011;19:989-
997. 
12. Katon W, Ciechanowski P. Impact of Major Depression on Chronic Medical Illness. Journal of 
Psychosomatic Research. 2002;53(4):859-863. 
13. Donohue J. Mental Health In The Medicare Part D Drug Benefit: A New Regulatory Model? Health Aff 
(Millwood). 2006;25(3):707-719. 
14. CMS. Open Door Forum on Risk Adjustment in Medicare Part D Prescription Drug Benefit. 2004. 
15. Hsu J, Huang J, Fung V, et al. Distributing $800 Billion: An Early Assessment Of Medicare Part D Risk 
Adjustment. Health Affairs. 2009;28(1):215-225. 
16. Huskamp HA, Stevenson D, Donohue J, Newhouse J, Keating N. Coverage and Prior Authorization of 
Psychotropic Drugs Under Medicare Part D. Psychiatr Serv. 2007;58(5):308-310. 
17. Foote S, Hogan C. Disability Profile and Health Care Costs of Medicare Beneficiaries Under Age Sixty-
Five. Health Aff (Millwood). 2001;20(6):242-253. 
18. Briesacher B, Stuart B, Kamal-Bahl S, Shea D. Medicare's Disabled Beneficiaries: The Forgotten 
Population in the Debate Over Drug Benefits. Menlo Park: Commonwealth Fund Henry J. Kaiser Family 
Foundation;2002. 
19. Cubanski J, Neuman P. Medicare Doesn't Work as Well for Younger, Disabled Beneficiaries as it does 
for Older Enrollees. Health Aff (Millwood). 2010;29(9):1725-1733. 
20. Nelson A, Reeder C, Dickson W. The Effect of a Medicaid Drug Copayment Program on the Utilization 
and Cost of Prescription Services. Medical Care. 1984;22(8):724-736. 
21. Bambauer K, Safran D, Ross-Degnan D, et al. Depression and Cost-Related Medication Nonadherence in 
Medicare Beneficiaries. Arch Gen Psychiatry. 2007;64:602-608. 
22. Kennedy J, Tuleu I, Mackay K. Unfilled Prescriptions of Medicare Beneficiaries: Prevalence, Reasons, 
and Types of Medicines Prescribed. J Manag Care Pharm. 2008;14(6):553-560. 
23. Association AP. Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington, DC,: 
American Psychiatric Association,; 1994. 
24. Pignone M, Gaynes B, Rushton J, et al. Screening for Depression in Adults: A Summary of the Evidence 
for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:765-776. 
65
  
 
 
 
25. Statistics USDOLBoL. Consumer Price Index. 2012; ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt. 
Accessed August 8, 2012. 
26. KFF. Fact Sheet: Medicare and Nonelderly People With Disabilities. 2010. 
http://www.kff.org/medicare/upload/8100.pdf. 
27. Berglund P. Getting the Most out of the SAS® Survey Procedures: Repeated Replication Methods, 
Subpopulation Analysis, and Missing Data Options in SAS® v9.2. 2009. 
28. SAS. SAS/STAT(R) 9.22 User's Guide Multiway Tables (Domain Analysis). 
http://support.sas.com/documentation/cdl/en/statug/63347/HTML/default/viewer.htm#statug_surveyfreq_
sect022.htm. Accessed August 12, 2012. 
29. Luber M, Meyers B, Williams-Russo P, et al. Depression and Service Utilization in Elderly Primary Care 
Patients. American Journal of Geriatric Psychiatry. 2001;9(4):169-176. 
30. Wang P, Schneeweiss S, Brookhard A, et al. Suboptimal Antidepressant Use in the Elderly. Journal of 
Clinical Psychopharmacology. 2005;25(2):118-126. 
31. FDA. Public Health Advisory: Suicidality in Children and Adolescents Being Treated with Anti-
depressant Medications. 2004 Safety Alerts for Human Medical Products 2004; 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm15
5488.htm. Accessed October 9, 2012. 
32. Libby A, Brent D, Morrato E, Orton H, Allen R, Valuck R. Decline in Treatment of Pediatric Depression 
After FDA Advisory on Risk of Suicidality With SSRIs. Am J Psychiatry. 2007;164:884-891. 
33. Valuck R, Libby A, Orton H, Morrato E, Allen R, Baldessarini R. Spillover Effects on Treatment of 
Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs. Am 
J Psychiatry. 2007;164:1198-1205. 
34. Libby A, Orton H, Valuck R. Persisting Decline in Depression Treatment After FDA Warnings. Arch Gen 
Psychiatry. 2009;66(6):633-639. 
35. Kroenke K, Spitzer M, Williams J. The Patient Health Questionnaire-2: Validity of a Two-Item 
Depression Screener. Medical Care. 2003;41(11):1284-1292. 
36. Madden J, Graves A, Zhang F, et al. Cost-Related Medication Nonadherence and Spending on Basic 
Needs Following Implementation of Medicare Part D. JAMA. 2008;299(16):1922-1928. 
37. Levy H, Weir D. Take-up of Medicare Part D: Results from the Health and Retirement Study. National 
Bureau of Economic Research2009. 
38. Heiss F, McFadden D, Winter J. Who Failed to Enroll in Medicare Part D, And Why? Early Results. 
Health Affairs. 2006;25(5):344-354. 
39. Docherty J. Barriers to the Diagnosis of Depression in Primary Care. Journal of Clinical Psychiatry. 
1997;58(Supplement 1):5-10. 
40. Foundation N. A Primer: Generic Drugs, Patents and the Pharmaceutical Marketplace. 2002. 
41. Hargrave E, Hoadley J, Cubanski J, Neuman P. Medicare Part D 2009 Data Spotlight: Ten Most 
Common Brand-Name Drugs. Henry J Kaiser Family Foundation;2009. 
42. Mark T, Gibson T, McGuigan K, Chu B. The Effects of Antidepressant Step Therapy Protocols on 
Pharmaceutical and Medical Utilization and Expenditures. American Journal of Psychiatry. 
2010;167:1202-1209. 
 
66
